Top Markets
Coin of the day
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
Rangering i aksjer #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Aksjekurs
$1,133.97
Sist synkronisert: 2026-09-15
Markedsverdi
$1.068T
Endring (1 dag)
-0.39%
Endring (1 år)
48.29%
Land
US
Handel Eli Lilly and Company (LLY)

Kategori

P/E-forhold for Eli Lilly and Company (LLY)
P/E-forhold per September 2026 TTM: 38.12
Ifølge Eli Lilly and Company sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 38.12. Ved slutten av 2024 hadde selskapet en P/E på 65.65.
P/E-forholdshistorikk for Eli Lilly and Company fra 2000 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 38.12 -18.49%
2025 46.76 -28.78%
2024 65.65 -34.38%
2023 100.04 79.72%
2022 55.66 17.95%
2021 47.19 80.98%
2020 26.08 72.36%
2019 15.13 -58.89%
2018 36.80 -108.45%
2017 -435.34 -1,571.91%
2016 29.58 -23.51%
2015 38.67 20.64%
2014 32.05 163.64%
2013 12.16 -12.09%
2012 13.83 29.88%
2011 10.65 39.32%
2010 7.64 -15.64%
2009 9.06 -142.59%
2008 -21.27 -207.90%
2007 19.71 -7.29%
2006 21.27 -31.61%
2005 31.09 -8.50%
2004 33.98 15.00%
2003 29.55 16.81%
2002 25.30 -16.89%
2001 30.44 -7.43%
2000 32.88 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
30.79 -19.22%
US
73.73 93.43%
US
22.25 -41.63%
CH
114.95 201.59%
US
22.23 -41.67%
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.